Wellbeing While Waiting: Effectiveness and implementation of youth social prescribing for young people awaiting CAMHS...

Prolonged waiting times for Child and Adolescent Mental Health Services (CAMHS) leave many young people without structured support while awaiting specialist treatment. Social prescribing has been proposed as a community-based adjunct within CAMHS pathways; however, evidence regarding its safety and clinical impact remains limited. Wellbeing While Waiting was a multi-site non-randomised controlled trial embedded within a hybrid type II implementation-effectiveness evaluation conducted across 11 CAMHS in England. The protocol was prospectively published prior to recruitment (BMC Psychiatry; https://doi.org/10.1186/s12888-023-04758-0 ). Between May 2023 and March 2025, 558 young people aged 11-18 years referred to CAMHS were enrolled (225 usual care; 333 social prescribing). Primary outcomes were anxiety and depression symptoms, total emotional and behavioural difficulties, and perceived stress. Secondary outcomes included resilience and wellbeing. No intervention-related adverse events were observed. On average, participants had 5 sessions with a Link Worker. Compared with usual care, no significant differences were observed in anxiety or depression symptoms. However, participants receiving social prescribing demonstrated significant improvements in total emotional and behavioural difficulties over six months, driven by reductions in conduct difficulties, hyperactivity and peer problems. Significant improvements for those receiving social prescribing were also found for prosocial behaviour and resilience. Within routine CAMHS pathways, no intervention-related adverse events were observed for social prescribing, and social prescribing was associated with improvements in behavioural and resilience-related outcomes, although not in anxiety or depressive symptoms. Findings suggest social prescribing may offer a valuable adjunct during delayed access to specialist treatment, with effects distinct from symptom-focused clinical therapies.